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In myocardial ischemia/reperfusion injury, the innate immune and subsequent inflammatory responses
play a crucial role in the extension of myocardial damage. Toll-like receptor 9 (TLR9) is a critical receptor
for recognizing unmethylated CpG motifs that mitochondria contain in their DNA, and induces inflam-
matory responses. The aim of this study was to elucidate the role of TLR9 in myocardial ischemia/
reperfusion injury.
Isolated hearts from TLR9-deficient and control wild-type mice were subjected to 35 min of global
ischemia, followed by 60min of reperfusion with Langendorff apparatus. Furthermore, wild-type mouse
hearts were infused with DNase I and subjected to ischemia/reperfusion.
Ablation of TLR9-mediated signaling pathway attenuates myocardial ischemia/reperfusion injury and
inflammatory responses, and digestion of extracellular mitochondrial DNA released from the infarct
heart partially improved myocardial ischemia/reperfusion injury with no effect on inflammatory re-
sponses. TLR9 could be a therapeutic target to reduce myocardial ischemia/reperfusion injury.
© 2019 Published by Elsevier Inc.1. Introduction
Coronary heart disease is the leading cause of death worldwide.
After myocardial infarction, myocardial reperfusion with primary
percutaneous coronary intervention (PCI) or thrombolytic therapy
is the most effective strategy to reduce infarct size and improve the
clinical outcome [1], while it also initiates myocardial injury and
paradoxically reduces the beneficial effect of reperfusion therapies.
The pathogenesis of this phenomenon, termed myocardial
ischemia/reperfusion (I/R) injury, is multifactorial [1]. The innate
immune and subsequent inflammatory responses play a critical
role in the extension of myocardial damage after myocardial I/R [2].
However, the molecular mechanisms responsible for initiating
sterile inflammatory responses during myocardial I/R injury have
not been fully elucidated.e et al., Ablation of Toll-like r
unications, https://doi.org/1Toll-like receptors (TLRs) were receptors for exogenous patho-
gens, initiating inflammation by immune cells [3]. Among TLRs,
TLR9 is the only receptor which detects unmethylated CpG motifs
in DNA [3e5], and is located intracellularly in endosomes and
endoplasmic reticulum [3,4]. The activation of TLR9 induces the
production of inflammatory cytokines such as tumor necrosis fac-
tor-a (TNFa), interleukin-6 (IL-6), interleukin-1b (IL-1b) and type1
interferons (IFNs) such as IFNb. TLR9 is expressed in immune cells
as well as non-immune cells such as cardiomyocytes [6].
Mitochondria contain unmethylated CpG motifs in their DNA.
Damaged mitochondria in response to hemodynamic stress are
degraded by autophagy-lysosomal system. We have reported that
DNase II, expressed in lysosomes, degrades mitochondrial DNA
(mtDNA) in autolysosomes, and incompletely digested mtDNA
binds to TLR9 and induces inflammatory responses in pressure
overloaded cardiomyocytes and heart failure [6].
The innate immune system in tissue injury is induced by
endogenous damage-associated molecular patterns (DAMPs)
released from damaged cells and contributes to sterileeceptor 9 attenuates myocardial ischemia/reperfusion injury in mice,
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damaged cells and causes inflammatory responses to tissue injury
as a DAMP [5]. It has been reported that focal myocardial necrosis
leads to mtDNA release into the circulation in patients with
myocardial infarction receiving PCI [7].
Thus, it was hypothesized that mtDNA released from necrotic
cardiomyocytes due to myocardial I/R activates TLR9 to induce
inflammation and cardiac injury. Many types of cells are involved in
the development of inflammation in the heart, namely car-
diomyocytes, inflammatory cells and fibroblasts. This study exam-
ined the effect of Tlr9 ablation on myocardial I/R injury in isolated
mouse hearts to exclude the involvement of circulating inflam-
matory cells.2. Materials and methods
2.1. Animals
All ex vivo procedures in this study were carried out in accor-
dance with the ARRIVE guidelines, the Guidance on the operation
of the Animals (Scientific Procedures) Act, 1986 (UK Home Office)
and EU Directive 2010/63/EU for animal experiments, and King's
College London Ethical Review Process Committee and UK Home
Office (Project Licence No. PPL70/7260 and 70/8889) approved the
experimental protocols. Age-matched (8e11 week-old) male con-
trol C57BL/6 wild-type (WT) mice and TLR9-deficient (TLR9KO)
mice with a C57BL/6 background were used in this study [6]. All
mice received humane care.2.2. Myocardial ischemia/reperfusion injury protocol
Isolated mouse hearts were Langendorff-perfused as previously
described [8,9]. In brief, mice were anesthetized with pentobarbi-
tone sodium and sodium heparin (140mg/kg body weight and 200
IU, respectively, intraperitoneally). Hearts were rapidly excised and
the aorta was cannulated. The hearts were then perfused with
oxygenated (95% O2þ 5% CO2) Krebs-Henseleit (K-H) buffer at 37 C
(pH7.4). The K-H buffer contained 118.5mM NaCl, 4.7mM KCl,
1.2mM KH2PO4, 25mM NaHCO3, 1.2mM MgSO4, 1.4mM CaCl2,
11mM glucose and 2.0mM sodium pyruvate. Perfusion was in the
non-recirculating Langendorff mode at a constant pressure
(80mmHg) and hearts were paced at 540 bpm. A left atrial resec-
tion was performed before insertion of a water-filled balloon
through the left atrium into the left ventricle. Left ventricular
pressure measurements were performed using the balloon inflated
to give an end-diastolic pressure (EDP) of 510mmHg. The EDP
was adjusted to 5e10mmHg at 5min before ischemia.
Langendorff-perfused hearts were stabilized for 20min and sub-
jected to 35min of global ischemia, followed by 20 or 60min of
reperfusion.2.3. Measurement of heart hemodynamic parameters
The following functional parameters were continuously recor-
ded using a computer-based data acquisition system (PowerLab/8S
with Chart 5 software, AD instruments, Gladstone, Australia): left
ventricular systolic pressure (LVSP), left ventricular end-diastolic
pressure (LVEDP), left ventricular developed pressure (LVDP,
LVDP¼ LVSP - LVEDP), the maximal value of the first derivative of
left ventricular pressure (dP/dtmax), the minimal value of the first
derivative of left ventricular pressure (dP/dtmin), heart rate and
coronary flow rate.Please cite this article as: R. Kitazume-Taneike et al., Ablation of Toll-like r
Biochemical and Biophysical Research Communications, https://doi.org/12.4. Assessment of myocardial infarct size
Infarct size was determined by 2,3,5-triphenyltetrazolium
chloride (TTC) staining. TTC in phosphate buffered solution (pH
7.4) was infused into the hearts for 10min at 60min of reperfusion.
Hearts were fixed in 10% formaldehyde, washed in phosphate
buffered saline, and then sliced into 1mm sections perpendicularly
along the long axis from apex to base. Viable myocardium was
stained in red, and infarcted tissue appeared white. The stained and
fixed heart slices were digitally photographed and the areas of
infarctionwere digitized using Image J software for planimetry. The
infarct area (TTC-negative sites) and the entire ventricle area were
measured by a blinded analyst. Ratios of the infarct area to the
entire ventricle area were calculated and expressed as infarct size.
2.5. Determination of myocardial necrotic injury
Cellular necrotic injury was evaluated by measurements of
creatine kinase (CK) released into the coronary effluent using an
EnzyChrom Creatine Kinase Assay Kit (BioAssay Systems). During
60min of reperfusion, all the coronary effluent dripping from
hearts was collected continuously and CK concentrations in the
effluent were measured by the Kit. CK release was calculated as the
product of coronary flow (mL/min) and CK concentrations (U/mL)
and normalized to heart weight (g).
2.6. Quantitative real-time RT-PCR
Total RNA from hearts was extracted using TRIzol Reagent
(Thermo Fisher Scientific) and complementary DNA (cDNA) was
synthesized using SuperScript II Reverse Transcriptase (Thermo
Fisher Scientific). Real-time PCR was performed using Power SYBR
Green PCRMasterMix (Thermo Fisher Scientific) and the sequences
of PCR primers are shown in Supplementary Table S1. Real-time
PCR standard curves were constructed using the corresponding
cDNA. All data were normalized to Gapdh content and are
expressed as fold increase over the control group.
2.7. Enzyme-linked immunosorbent assay (ELISA) for IL-6 and IFNb
in the coronary effluent
All the coronary effluent from hearts was collected continuously
during 60min of reperfusion, frozen in liquid nitrogen and ana-
lysed by ELISA according to the manufacturer's protocols (IL-6:
M000B, IFNb: MIFNB0, R&D Systems). Release of IL-6 and IFNb from
the heart was calculated as the product of quantity of coronary
effluent (mL) during reperfusion and protein concentrations (ng/
mL), and normalized to heart weight (g).
2.8. DNase I treatment to WT and TLR9KO hearts
DNase I (Sigma Aldrich, D4263) was diluted in K-H buffer
(DNase I 10 Kunitz units per mL of K-H buffer). Langendorff-
perfused hearts were stabilized for 10min and perfused under
constant pressure (80mmHg) with oxygenated DNase I dilution
buffer for 20min, followed by 35min of myocardial ischemia and
60min of reperfusion. As a control buffer, Langendorff-perfused
hearts were perfused with K-H buffer. During 60min of reperfu-
sion, all the coronary effluent dripping from WT hearts was
collected continuously for CK measurement and WT hearts for
measuring the mRNA expression of inflammatory cytokines were
obtained at the end of the stabilization period and 60min of
reperfusion. For inactivated DNase I perfusion, DNase I diluted in K-
H buffer was inactivated by heating (68 C, 10min) before
perfusion.eceptor 9 attenuates myocardial ischemia/reperfusion injury in mice,
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The coronary effluent from hearts was collected from 0 to 2min
of reperfusion and total DNAwas isolated using the DNeasy Blood&
Tissue Kit (QIAGEN) and purified by phenol-chloroform extraction
and ethanol precipitation. For mtDNA, quantitative real-time PCR
was performed using the TaqMan Gene Expression Master Mix
(Thermo Fisher Scientific). The PCR primers for Cox1 were pur-
chased from Thermo Fisher Scientific (Mm04225243_g1). PCR
standard curves were constructed using mtDNA isolated from
mouse embryonic fibroblast (MEF) cells. The cells were homoge-
nized and the mitochondrial fraction was isolated using sucrose
density gradient methods [10]. The mtDNA from the mitochondrial
fractionwas extracted and purified using the QIAamp DNAMini Kit
(QIAGEN). The enrichment of the mtDNA fractionwas confirmed by
quantitative PCR analysis using mtDNA specific primers [11]. The
amount of mtDNA was calculated as the product of coronary flow
rate (mL/min) and mtDNA concentrations (ng/mL) [7].2.10. Statistical analysis
Analysed results are expressed as the mean± SEM. The differ-
ence between two groups was evaluated using a Student's t-test,
and time-lapse data were assessed by two-way ANOVA repeated
measures followed by Bonferroni's post hoc test. GraphPad Prism
5.0 was used for data analyses. A value of P< 0.05 was considered
statistically significant.Fig. 1. Cardiac function during myocardial ischemia/reperfusion in Langendorff-perfused co
ventricular pressure (LVP) data. b Percent left ventricular developed pressure (%LVDP), left ve
ventricular pressure (dP/dtmax), the minimal value of the first derivative of left ventricular pr
mean± SEM of data from n¼ 6 per group. *P< 0.05 vs WT at the corresponding time point
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3.1. Effect of Tlr9 ablation on myocardial function during I/R
To investigate the role of TLR9 in cardiomyocytes in myocardial
I/R, global ischemia and reperfusion was performed to isolated
hearts from TLR9KO and control WT mice. Cardiac functional pa-
rameters such as LVDP, LVEDP, dP/dtmax and dP/dtmin (Fig. 1aeb)
and coronary flow rate were not different at the end of the stabi-
lization period between TLR9KO andWT hearts [coronary flow rate
(mL/min), WT: 2.7± 0.1 vs TLR9KO: 2.8± 0.1, n¼ 6 per group]. After
35min of ischemia, LVDP, dP/dtmax and dP/dtmin decreased, and
LVEDP increased in both groups compared to those at the end of the
stabilization period. However, there were no differences in LVDP,
LVEDP, dP/dtmax or dP/dtmin at the end of ischemia between both
groups. During reperfusion, LVDP, LVEDP, dP/dtmax and dP/dtmin
recovered in both groups. However, at 5min of reperfusion, TLR9KO
hearts showed dramatic recovery of LVDP, LVEDP, dP/dtmax and dP/
dtmin compared to WT hearts. The significant improvements in
those parameters in TLR9KO hearts continued until 60min of
reperfusion. These results suggest that Tlr9 ablation had no effect
on cardiac dysfunction caused by ischemia, but protected cardiac
function against I/R injury.3.2. Effect of Tlr9 ablation on myocardial necrosis caused by I/R
To examine the effect of TLR9 signaling on myocardial necrosis,
infarct size was measured using TTC staining at 60min ofntrol C57BL/6 (WT) and TLR9-deficient (TLR9KO) mouse hearts. a Representative left
ntricular end-diastolic pressure (LVEDP), the maximal value of the first derivative of left
essure (dP/dtmin). Closed circles indicate WT, open circles TLR9KO. Values represent the
.
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significantly smaller than that inWT hearts after I/R. CK release into
the coronary effluent during reperfusion was measured using a CK
Assay Kit (Fig. 2c). The level of CK release into the effluent in
TLR9KO hearts was significantly lower than that in WT after I/R.
These results indicate that greater recovery of cardiac function after
I/R in TLR9KO mice was associated with myocardial necrosis.
3.3. Effect of Tlr9 ablation on the inflammatory cytokine during I/R
To evaluate the role of TLR9 on inflammatory responses during I/
R, mRNA levels of inflammatory cytokines at the end of the stabi-
lization period (Pre) and ischemia, and at 20 and 60min after
reperfusion were examined (Fig. 3). At the end of stabilization and
ischemia, there were no significant differences in mRNA levels of
inflammatory cytokines such as Tnfa, Il6, Mcp1, Il10, Il1b or Ifnb1
between TLR9KO and WT hearts. However, mRNA levels of Tnfa, Il6
and Mcp1 were elevated at 60min of reperfusion compared to
those at the end of stabilization period in both TLR9KO and WT
hearts. The mRNA levels were lower in TLR9KO hearts than those in
WT hearts. Il10, as a potent anti-inflammatory cytokine, showed a
similar pattern to that of Tnfa or Il6. AlthoughmRNA levels of Il1b in
both TLR9KO and WT hearts and Ifnb1 in WT hearts were elevated
at 60min of reperfusion, there were no significant differences be-
tween both groups. The levels of Ifna4 and Ifng mRNA expressions
in the hearts were under the detectable limit during I/R (data not
shown). These results suggest that ablation of Tlr9 attenuated the
inflammatory response in I/R.
Furthermore, the protein levels of IL-6 and IFNb in the coronary
effluent collected during reperfusion were measured using ELISA
(Supplementary Fig. S1). The quantity of IL-6 was significantly
suppressed in the effluent from TLR9KO hearts compared toWT. On
the other hand, IFNb was not detected (data not shown).
3.4. Effect of DNase I treatment on cardiac injury and inflammatory
responses during I/R
To elucidate the contribution of mtDNA released from necroticFig. 2. Assessment of myocardial necrosis after myocardial ischemia/reperfusion. a
Representative images of 2,3,5-triphenyltetrazolium chloride (TTC) stained mouse
heart sections. b Infarct size measured by TTC staining. c Creatine kinase (CK) release
into the coronary effluent. Values represent the mean ± SEM of data from n¼ 6 per
group. *P< 0.05 vs WT.
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perfused to hearts from WT mice during I/R. First, levels of Cox1
DNA, derived frommtDNA, were measured in the coronary effluent
to examine whether DNase I perfusion can degrade extracellular
mtDNA. DNase I perfusion to isolatedWT hearts decreased the level
of mtDNA release into the effluent just after the beginning of
reperfusion (Fig. 4a).
At the end of the stabilization period and 35min of ischemia,
LVDP, LVEDP (Fig. 4b), dP/dtmax and dP/dtmin (data not shown) were
not different between DNase I perfused and control hearts. Coro-
nary flow rate at the end of the stabilization period were not
different between both groups, either [coronary flow rate (mL/
min), control: 2.5± 0.2 vs DNase I perfused heart: 2.1± 0.2, n¼ 5
per group)]. However, during reperfusion, DNase I perfused hearts
showed improvement of LVDP and LVEDP compared to control
hearts, which was evident from 15min for LVDP, and 5min for
LVEDP after reperfusion. The partial improvement of cardiac
dysfunction was observed until the end of 60min of reperfusion
[dP/dtmax (mmHg/s) 1085± 222 vs 1791± 168; dP/dtmin (mmHg/
s), 935± 164 vs 1362± 87, control vs DNase I perfused heart,
P< 0.05, n¼ 5 per group]. As a control buffer for DNase I perfusion
study, WT hearts were also perfused with inactivated DNase I.
There was no difference in cardiac function between inactivated
DNase I and control K-H buffer perfused hearts (Supplementary
Fig. S2). DNase I perfused WT hearts showed significantly smaller
infarct size than WT hearts perfused with control buffer (Fig. 4c).
The level of CK release into the effluent was significantly lower in
DNase I perfused hearts than that in control during reperfusion
(Fig. 4d).
Although the levels of mRNA expression of Tnfa and Il6 (Fig. 4e)
as well as Mcp1, Il10, Il1b and Ifnb1 (data not shown) in the hearts
were elevated at 60min of reperfusion in both groups, there were
no significant differences in the mRNA expression levels between
control and DNase I perfused hearts. This suggests that digestion of
mtDNA released from the necrotic myocardium induced partial
recovery of cardiac dysfunction and myocardial necrosis during I/R,
but had no effect on the inflammatory responses.
Furthermore, DNase I was perfused to isolated hearts from
TLR9KOmice during I/R. Therewas no difference in cardiac function
between TLR9KO hearts perfused with DNase I and TLR9KO hearts
perfused with control K-H buffer (Supplementary Fig. S3). This
result suggests that non-TLR9 receptors were not main players
mediating mtDNA signaling in this model.
4. Discussion
This study showed that ablation of the myocardial TLR9
signaling pathway attenuated inflammatory responses and
myocardial I/R injury and that mtDNA released from necrotic car-
diomyocytes could activate TLR9.
The role of TLR9 in myocardial I/R injury has been investigated
using an in vivo model, where TLR9 was activated by the admin-
istration of unmethylated CpG oligonucleotides. Activation of TLR9
prior to I/R improved cardiac function and reduced infarct size
[12,13], while TLR9 activation upon onset of ischemia showed no
effect on infarct size despite causing myocardial inflammation [14].
However, Tlr9 ablation reduced infarct size in I/R hearts [13]. In the
present study, global ischemia was performed in an ex vivo model
to eliminate the contribution of circulating immune cells, showing
that ablation of Tlr9 had no effect on cardiac function during
ischemia, but improved recovery of both systolic and diastolic
cardiac function during reperfusion. The protectionwas initiated in
the early phase of reperfusion, indicating that TLR9 activation in the
heart during reperfusion is detrimental to the heart. The reduction
in the infarct size and CK release into the coronary effluent suggestseceptor 9 attenuates myocardial ischemia/reperfusion injury in mice,
0.1016/j.bbrc.2019.05.150
Fig. 3. The mRNA expression levels of inflammatory cytokines derived from myocardium during myocardial ischemia/reperfusion. The mRNA levels of Tnfa, Il6, Mcp1, Il10, Il1b and
Ifnb1 were normalized to Gapdh and are shown as fold increase over levels in the control C57BL/6 (WT) group at the end of stabilization period (Pre). Closed bars indicate WT, open
bars TLR9-deficient (TLR9KO) hearts. Values represent the mean± SEM of data from n¼ 4e12 per group. *P< 0.05 vs the corresponding group at the end of stabilization period (Pre),
yP< 0.05 vs WT at the corresponding time point.
Fig. 4. Effect of DNase I treatment during ischemia/reperfusion on Langendorff-perfused control C57BL/6 hearts in myocardial ischemia/reperfusion injury. a Mitochondrial DNA
(mtDNA) release into the coronary effluent. Values represent the mean ± SEM of data from n¼ 6 per group. *P< 0.05 vs control. b Percent left ventricular developed pressure (%
LVDP) and left ventricular end-diastolic pressure (LVEDP). Closed circles indicate control, open circles DNase I perfused hearts. Values represent the mean± SEM of data from n¼ 5
per group. *P< 0.05 vs control at the corresponding time point. c Infarct size measured by TTC staining. Values represent the mean± SEM of data from n¼ 6 per group. *P< 0.05 vs
control. d Creatine kinase (CK) release in the coronary effluent. Values represent the mean± SEM of data from n¼ 6 per group. *P< 0.05 vs control. e The mRNA expression levels of
inflammatory cytokines derived from the myocardium during myocardial ischemia/reperfusion. The mRNA levels of Tnfa and Il6 were normalized to Gapdh and are shown as fold
increase over levels in the control group at the end of stabilization period (Pre). Closed bars indicate control, open bars DNase I perfused hearts. Values represent the mean ± SEM of
data from n¼ 12 per group. *P< 0.05 vs the corresponding group at Pre.
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caused by the induction of cardiomyocyte necrotic death.
For the first time, we showed that ablation of TLR9 in the heart
attenuates inflammatory responses in I/R without the involvement
of circulating immune cells in an ex vivo study. Inflammatory cy-
tokines such as TNFa and IL-6 are reported to depress myocardial
function in an ex vivo crystalloid-superfused papillary muscle
preparation [15]. Initially, it was hypothesized that inflammatory
cytokines are main contributors to cardiac dysfunction in I/R.
However, recovery of cardiac function in TLR9KO hearts wasPlease cite this article as: R. Kitazume-Taneike et al., Ablation of Toll-like r
Biochemical and Biophysical Research Communications, https://doi.org/1detected in the early phase of reperfusion before downregulation of
inflammatory cytokines was detected. In addition, DNase I treat-
ment attenuated I/R injury but showed no effect on inflammatory
responses. A previously reported study revealed inflammation-
independent roles of TLR9 in cardiomyocytes [16]. Shintani et al.
reported that TLR9 stimulation reduces energy substrates and in-
creases the AMP/ATP ratio, subsequently activating AMP-
dependent kinase, leading to increase tolerance against hypoxia
in cardiomyocytes without inducing the canonical inflammatory
responses. We have previously reported that TLR9 prevents cardiaceceptor 9 attenuates myocardial ischemia/reperfusion injury in mice,
0.1016/j.bbrc.2019.05.150
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differentiation of cardiac fibroblasts [17]. It is possible that cardiac
dysfunction in I/R may be not only induced by TLR9-mediated in-
flammatory cytokine activation but also mediated through the
inflammation-independent TLR9 signaling pathway.
Extracellular mtDNA can be internalized into cardiomyocytes
inducing the TLR9 signaling and cell death [18]. DNase I treatment
reduced infarct size in myocardial I/R open-chest or isolated
perfused rat hearts [19]. Furthermore, the combination of DNase I
and mitochondria-targeted endonuclease III, which would main-
tain mitochondrial integrity in the ischemic cardiomyocytes, can
produce additive protection against myocardial I/R injury [19]. On
the other hand, we found that intracellular mtDNA escaping from
autophagic degradation can cell-autonomously activate TLR9 and
induce the inflammatory response in pressure overloaded car-
diomyocytes [6]. In this study, it was examined whether the
degradation of extracellular mtDNA can rescue the cardiac phe-
notypes and inhibit the inflammatory responses in I/R injury by
perfusing DNase I into the heart. The inflammatory responses,
which were inhibited by Tlr9 ablation, were not affected by DNase I
perfusion in I/R hearts. DNase I is supposed to degrade mainly
extracellular mtDNA and prevent extracellular mtDNA from being
internalized into cardiomyocytes. We do not know the exact reason
why mtDNA internalized from extracellular space and that gener-
ated cell-autonomously inside the cell have apparently different
outcome following TLR9 activation. TLR9 locates intracellularly in
endosomes and endoplasmic reticulum [3,4] as well as autoly-
somes [6]. Each type of mtDNA might activate distinct TLR9, which
has different subcellular localization and function.
This study revealed that TLR9 in the heart may be a critical
contributor to the final infarct size and could be a therapeutic target
in myocardial I/R injury. TLR9 has a wide variety of functions in
cardiac disease, so further research is needed to determine the risks
and benefits of TLR9 as a therapeutic target and to access the
method of application.
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